146 results on '"Luttwak, Efrat"'
Search Results
2. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis
3. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies
4. What is the best salvage therapy for Hodgkin lymphoma?
5. Impact of Tocilizumab on CAR-T Cells Outcome and Toxicity: Results from a Large B Cell Lymphoma Cohort
6. Digital Droplet PCR Based Monitoring of CAR-T Cell Expansion in Lymphoma Patients: Impact on Treatment Outcome
7. Site-Specific Response Rates in Large B-Cell Lymphomas Treated with CD19-CART Therapy.
8. Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series
9. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
10. Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients
11. Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients
12. Treatment with low‐dose, single‐agent belantamab mafodotin is safe and provides long‐term responses in heavily pretreated multiple myeloma patients.
13. POSTER: MM-362 Multiple Myeloma Oligosecretory Relapse: A Cross-Sectional Historical Cohort Study
14. MM-362 Multiple Myeloma Oligosecretory Relapse: A Cross-Sectional Historical Cohort Study
15. Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomes
16. P942: MULTIPLE MYELOMA OLIGOSECRETORY RELAPSE- A CROSS SECTIONAL HISTORICAL COHORT STUDY
17. P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY.
18. The efficacy of tixagevimab–cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry
19. Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy
20. Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study
21. Vagal Nerve Activity Predicts Prognosis in Diffused Large B-Cell Lymphoma and Multiple Myeloma
22. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to anti CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
23. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
24. Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.
25. A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)
26. P-114: Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study
27. Lymphoproliferative disease detected by breast cancer screening
28. Sequencing Therapies in Relapsed/ Refractory Large B-cell Lymphoma to Optimize the Chance of Cure
29. COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge
30. Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
31. Is There a Role for [18F]FDG PET-CT in Staging MALT Lymphoma?
32. BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses
33. Using Machine Learning Methods to Explore the Role of Non-Coding RNAs in DLBCL
34. Multiple Myeloma Oligosecretory Relapse, a Non-Negligible Phenomenon. Frequency, Clinical Characteristics and Outcomes in a Single Center
35. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies
36. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma
37. Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma
38. Higher CD4+ T Cell Counts after CAR-T in Large B-Cell Lymphomas Are Significantly Associated with Better Overall Survival
39. The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data
40. Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series
41. Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review
42. Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study
43. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.
44. Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myeloma
45. Outcomes of Post-Induction Bortezomib Therapy in Patients with Newly diagnosed Multiple Myeloma: A Multi-Center Retrospective Observational Study
46. Cryoablative Surgery for Patients with Radiotherapy Resistant Solitary Plasmacytoma: Report of Two Cases
47. Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review.
48. 18F-FDG PET/CT Imaging Biomarkers for CAR-T Cell Therapy Outcomes in Large-B-Cell Lymphoma
49. A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)
50. Impact of Early Histological Transformation on Survival in Patients with Follicular Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.